microbiology

Without standardized, strain-level analysis, and clinically meaningful benchmarks, microbiome science will struggle to move from research into routine care.

New study uses simulations and machine learning to identify a single, high-impact interaction within a viral fusion protein, highlighting a potential new target for antiviral drug development.

Automation may help address longstanding bottlenecks in CAR-T and TCR-T development

Researchers highlight how intra-tumoral microbiota shape tumor growth, drug resistance, and treatment response.

Lonza strengthens its pharmaceutical quality control portfolio through the acquisition of Redberry, enabling faster and more reliable microbial testing.

Strategies including parasite-based vaccines, mosquito-transmission blockers, and antibody drugs are promising new ways to target the disease.  

DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.

Reengineering the way microbial colonies are picked, plated, and analyzed, with over 95% efficiency and nearly 100% accuracy

A new antifungal drug, mandimycin, tackles resistant fungal strains with a never-before-seen mechanism that avoids kidney toxicity.

Virus-inspired delivery methods enable gene editing of dysregulated microbes.